Mariana Silveira Mello Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mariana Silveira Mello Silva has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ana Vitória Costa
Universidade Federal de Pelotas, Brasil
1 shared publication - Anella Saggese
Department of Biology, Federico II University of Naples, 80126 Naples, Italy
1 shared publication Carlos James Scaini
Parasitology Laboratory, Federal University of Rio Grande (FURG). Faculty of Medicine (FAMED), Federal University of Rio Grande (FURG), Rio Grande, Brazil
1 shared publicationDaniela Fernandes Ramos
New drug development Laboratory (LADEFA), FURG. Faculty of Medicine (FAMED), Federal University of Rio Grande (FURG), Rio Grande, Brazil
1 shared publication- Ezio Ricca
Department of Biology, Federico II University of Naples, 80126 Naples, Italy
1 shared publication - Frederico Schmitt Kremer
Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Capão do Leão CEP 96160-000, RS, Brazil
1 shared publication
Latest Publications
- Open Access
- 24 September 2026
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 57 (1) , 279
Organic acid-associated antimicrobial and antibiofilm activity of Lactobacillus rhamnosus ATCC 7469 against Acinetobacter baumannii and Staphylococcus aureus
Considering the relevance of biofilms in bacterial resistance and the need for innovative therapies against pathogenic microorganisms, alternative strategies using probiotics as antimicrobial agents have emerged. This study aimed to evaluate the antimicrobial and antibiofilm activities of the cell-free supernatant (CFS) of Lactobacillus rhamnosus ATCC 7469 against biofilm-forming strains of Acinetobacter baumannii and Staphylococcus aureus . The activity of CFS was evaluated against A. baumannii ATCC 19606, A. baumannii 301, S. aureus ATCC 12598, and S. aureus ATCC 29213. Antimicrobial activity against planktonic cells, inhibition of biofilm formation, and destruction of mature biofilms were assessed at different CFS dilutions. The corresponding concentrations of lactic and acetic acids were determined by high-performance liquid chromatography (HPLC). CFS showed high antimicrobial activity, with growth inhibition ranging from 88.26% to 100% at the two highest concentrations tested (197.8/108.7 and 107.0/54.5 mM lactic/acetic acid). At 57.8/28.3 mM, growth inhibition ranged from 60.05% to 81.65%, whereas at 27.2/13.5 mM it ranged from 21.12% to 41.03%. CFS also strongly inhibited biofilm formation, with inhibition rates ranging from 66.17% to 100%, whereas destruction of mature biofilms ranged from 24.75% to 88.11%. HPLC analysis demonstrated the presence of lactic and acetic acids in the CFS, with lactic acid being the predominant organic acid detected. Neutralization of the CFS to pH 7.0 markedly reduced its antimicrobial and antibiofilm activities, supporting an important contribution of acidity and acid-associated components to the observed effects. Overall, L. rhamnosus ATCC 7469 CFS exhibited substantial antimicrobial and antibiofilm activity against A. baumannii and S. aureus , supporting further investigation of Lactobacillus -derived CFS as a potential local antimicrobial strategy.
- 24 September 2026
- Published by Springer Nature in Brazilian Journal of Microbiology
- Vol. 57 (1) , 279
Open AccessOrganic acid-associated antimicrobial and antibiofilm activity of Lactobacillus rhamnosus ATCC 7469 against Acinetobacter baumannii and Staphylococcus aureus
Considering the relevance of biofilms in bacterial resistance and the need for innovative therapies against pathogenic microorganisms, alternative strategies using probiotics as antimicrobial agents have emerged. This study aimed to evaluate the antimicrobial and antibiofilm activities of the cell-free supernatant (CFS) of Lactobacillus rhamnosus ATCC 7469 against biofilm-forming strains of Acinetobacter baumannii and Staphylococcus aureus . The activity of CFS was evaluated against A. baumannii ATCC 19606, A. baumannii 301, S. aureus ATCC 12598, and S. aureus ATCC 29213. Antimicrobial activity against planktonic cells, inhibition of biofilm formation, and destruction of mature biofilms were assessed at different CFS dilutions. The corresponding concentrations of lactic and acetic acids were determined by high-performance liquid chromatography (HPLC). CFS showed high antimicrobial activity, with growth inhibition ranging from 88.26% to 100% at the two highest concentrations tested (197.8/108.7 and 107.0/54.5 mM lactic/acetic acid). At 57.8/28.3 mM, growth inhibition ranged from 60.05% to 81.65%, whereas at 27.2/13.5 mM it ranged from 21.12% to 41.03%. CFS also strongly inhibited biofilm formation, with inhibition rates ranging from 66.17% to 100%, whereas destruction of mature biofilms ranged from 24.75% to 88.11%. HPLC analysis demonstrated the presence of lactic and acetic acids in the CFS, with lactic acid being the predominant organic acid detected. Neutralization of the CFS to pH 7.0 markedly reduced its antimicrobial and antibiofilm activities, supporting an important contribution of acidity and acid-associated components to the observed effects. Overall, L. rhamnosus ATCC 7469 CFS exhibited substantial antimicrobial and antibiofilm activity against A. baumannii and S. aureus , supporting further investigation of Lactobacillus -derived CFS as a potential local antimicrobial strategy.
- Open Access
- 18 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7364
In Silico and In Vitro Characterization of Fecal Spore-Forming Bacteria with Probiotic Potential
The search for next-generation probiotics derived from the human gut microbiota has intensified due to their potential beneficial effects in modulating immunity and preventing diseases. Spore-forming bacteria are attractive probiotic candidates due to their functional traits and unique resilience, which offer high stability to commercial formulations. In this study, spore-forming bacteria isolated from human fecal samples were screened. Two strains, Bacillus spizizenii A1 and Priestia megaterium F6, were identified as non-hemolytic and not resistant to a panel of antibiotics relevant for spore formers. Both strains were characterized by using in silico and in vitro approaches, demonstrating relevant probiotic potential. The comparative analysis indicated B. spizizenii A1 as the most promising probiotic candidate due to the resistance of its spores to simulated gastric conditions and for its antioxidant, antimicrobial, and antibiofilm activities. Strain A1 combines a safety profile with functional probiotic traits and is therefore a strong candidate for further in vivo evaluation and future development as a next-generation probiotic.
- 18 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (16) , 7364
Open AccessIn Silico and In Vitro Characterization of Fecal Spore-Forming Bacteria with Probiotic Potential
The search for next-generation probiotics derived from the human gut microbiota has intensified due to their potential beneficial effects in modulating immunity and preventing diseases. Spore-forming bacteria are attractive probiotic candidates due to their functional traits and unique resilience, which offer high stability to commercial formulations. In this study, spore-forming bacteria isolated from human fecal samples were screened. Two strains, Bacillus spizizenii A1 and Priestia megaterium F6, were identified as non-hemolytic and not resistant to a panel of antibiotics relevant for spore formers. Both strains were characterized by using in silico and in vitro approaches, demonstrating relevant probiotic potential. The comparative analysis indicated B. spizizenii A1 as the most promising probiotic candidate due to the resistance of its spores to simulated gastric conditions and for its antioxidant, antimicrobial, and antibiofilm activities. Strain A1 combines a safety profile with functional probiotic traits and is therefore a strong candidate for further in vivo evaluation and future development as a next-generation probiotic.